optomap®

REGISTERED OCT CAN INCREASE THE SENSITIVITY AND EFFICIENCY OF EXAM



Combining optomap with SD-OCT increases the identification of macular pathology when compared with fundus imaging alone by 29.4%[1] and supports the detection of glaucoma with high accuracy.[2]

- *Monaco* is the first retinal imaging device combining single capture 200° ultra-widefield (UWF™) with SD-OCT.
- *Monaco* can capture color and **opto**map *af* images along with posterior pole OCT scans of both eyes in as little as 90 seconds. Simultaneous **opto**map and OCT have been shown to benefit the evaluation and management of retinal pathologies.[3]
- *Monaco* includes a comprehensive reference database (RDB) which follows new best practice, state of the art guidelines for optic nerve head (ONH) size allowing for more accurate glaucoma predictions.
- Multi-modal imaging allows for the reduction of ungradables to less than 1% and of false positives by 58%.[1]
- Adding SD-OCT to UWF imaging helps in identifying diabetic macular edema (DME) and epiretinal membrane (ERM), increasing sensitivity for central pole lesions compared with fundus imaging alone. A screening program that implemented *Monaco* found 14% were referrable for diabetic retinopathy (DR).[1]
- Glaucomatous defects measured with *Monaco* correlate well with visual field results and Cirrus.[4, 5]
- *Monaco* ONH distribution reporting and measures correlate with Cirrus.[5]
- *Monaco* retinal thickness measurements strongly correlate with and are comparable to the Heidelberg Spectralis OCT.[3]

"Integrated system [Monaco] provides quality fundus photographs as well as OCT, obviates the need for two separate instruments and likely improves the clinic flow."[3]

See how **opto**map will help you manage your patients. For more information call **800-854-3039** or **BDS@optos.com**.

Nikon

optos®

CLINICAL SUMMARY

Additional details about the utility of *Monaco*



Proliferative Diabetic Retinopathy with DME previously treated with panretinal photocoagulation.

- *Monaco* combines **opto**map UWF technology with SD-OCT creating a fast, convenient, multi-modal imaging tool. *Monaco* can produce 200°, single-capture retinal images of unrivaled clarity and can display a six-image overview including *color*, *af*, and OCT of both eyes in as little as 90 seconds.
- The includes five scan types: Line Scan, Raster Scan, Retina Topography Scan, ONH Topography Scan, Retinal Nerve Fiber layer (RNFL) Scan.
- The comprehensive US cleared RDB included with *Monaco* is based on 879 subjects, without pathology, collected across 9 clinical sites. Subjects ranged from 22-84 years old (average age: 51 years old), 61.9% were female and ethnicities included were: 57% White, 16% Asian, 14% African American, 15% Hispanic.
- The RDB enables the results of OCT analysis to be shown in relation to 1%, 5%, 95% and 99% of the RDB population.
- *Monaco* follows new best practice, state of the art guidelines for ONH size which allows for more accurate glaucoma predictions. ONH Size Covariate: Small optic discs (disc area <1.76mm2 : 33%); Medium optic discs (disc area 1.76mm2 - 2.15mm2 : 37%); Large optic discs (disc area >2.15mm2 : 30%).

*There are regionally approved databases which vary in number, composition and presentation state.

1. Aiello. Integrating Macular Optical Coherence Tomography with Ultrawide Field Imaging in a Diabetic Retinopathy Telemedicine Program Using a Single Device. Retina. 2023. 2. Chaglasian. Accuracy of Glaucoma Detection with a Novel Imaging Device: Combined UWF-SLO and SD-OCT. ARVO 2024. 3. Chalam. Baseline retinal thickness measurements with a novel integrated imaging system (concurrent optical coherence tomography and fundus photography) positively correlates with spectralis optical coherence tomography. Quant Imaging Med Surg 2022;12(1):417-424. 4. E. Sinai. Structure and Function Relationship in Glaucoma with a Novel Multi- Modal Imaging Device Combining UWF-SLO and SD-OCT. ARVO 2024. 5. A. Speilburg. The Normal Distribution of Disc Area on a Combined UWF-SLO + SD-OCT device with Comparison to SD-OCT. ARVO 2024.

Optos UK/Europe
+44 (0)1383 843350
ics@optos.com

Optos North America
800 854 3039
usinfo@optos.com

Optos DACH
DE: 0800 72 36 805
AT: 0800 24 48 86
CH: 0800 55 87 39
ics@optos.com

Optos Australia
+61 8 8444 6500
auinfo@optos.com

Contact us: